The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers
- PMID: 12142085
- DOI: 10.1016/s0304-3835(02)00318-x
The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers
Abstract
The influence of tetramerisation on the properties of the p53 mutants is poorly understood. We describe here the influence of the tetramerisation on the properties of the oncogenic mutant Asp281Gly. We show that despite being both nuclear the tetrameric Asp281Gly and the monomeric Asp281GlyLeu344Pro proteins have different properties: only Asp281Gly stimulates the transcription of the multidrug resistance-1 gene promoter and induces cisplatin resistance in Saos-2 cells. Moreover, we identify a 130-kDa protein that specifically interacts with Asp281Gly but not with Asp281GlyLeu344Pro. This suggests that tetramerisation is important for the properties of the p53 mutants and that these properties might be mediated via protein-protein interactions.
Similar articles
-
p53 mutants without a functional tetramerisation domain are not oncogenic.J Mol Biol. 1999 Mar 12;286(5):1269-74. doi: 10.1006/jmbi.1999.2563. J Mol Biol. 1999. PMID: 10064694
-
Human ARF binds E2F1 and inhibits its transcriptional activity.Oncogene. 2001 Mar 1;20(9):1033-41. doi: 10.1038/sj.onc.1204220. Oncogene. 2001. PMID: 11314038
-
Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.Oncogene. 2002 Jan 10;21(2):176-89. doi: 10.1038/sj.onc.1205035. Oncogene. 2002. PMID: 11803461
-
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.Cancer Res. 1996 Feb 1;56(3):556-62. Cancer Res. 1996. PMID: 8564971
-
When mutants gain new powers: news from the mutant p53 field.Nat Rev Cancer. 2009 Oct;9(10):701-13. doi: 10.1038/nrc2693. Epub 2009 Aug 20. Nat Rev Cancer. 2009. PMID: 19693097 Review.
Cited by
-
Identification of GRO1 as a critical determinant for mutant p53 gain of function.J Biol Chem. 2009 May 1;284(18):12178-87. doi: 10.1074/jbc.M900994200. Epub 2009 Mar 3. J Biol Chem. 2009. PMID: 19258312 Free PMC article.
-
Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.Trends Pharmacol Sci. 2017 Oct;38(10):908-927. doi: 10.1016/j.tips.2017.07.004. Epub 2017 Aug 14. Trends Pharmacol Sci. 2017. PMID: 28818333 Free PMC article. Review.
-
Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.Cancer Res. 2008 Aug 15;68(16):6789-96. doi: 10.1158/0008-5472.CAN-08-0810. Cancer Res. 2008. PMID: 18701504 Free PMC article.
-
Mutant p53 in cancer: new functions and therapeutic opportunities.Cancer Cell. 2014 Mar 17;25(3):304-17. doi: 10.1016/j.ccr.2014.01.021. Cancer Cell. 2014. PMID: 24651012 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous